[go: up one dir, main page]

WO2007053194A3 - Modulation des dysfonctionnements de la barriere cellulaire - Google Patents

Modulation des dysfonctionnements de la barriere cellulaire Download PDF

Info

Publication number
WO2007053194A3
WO2007053194A3 PCT/US2006/021604 US2006021604W WO2007053194A3 WO 2007053194 A3 WO2007053194 A3 WO 2007053194A3 US 2006021604 W US2006021604 W US 2006021604W WO 2007053194 A3 WO2007053194 A3 WO 2007053194A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
cell barrier
pseudomonas
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/021604
Other languages
English (en)
Other versions
WO2007053194A2 (fr
Inventor
John C Alverdy
Jonathan Moss
Mark W Lingen
Patrick A Singleton
Joe G N Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/007892 external-priority patent/WO2006096626A2/fr
Priority to US11/914,984 priority Critical patent/US20080194611A1/en
Priority to AU2006309292A priority patent/AU2006309292A1/en
Priority to EP06844131A priority patent/EP1901742A2/fr
Priority to JP2008514938A priority patent/JP2008542395A/ja
Priority to CA002609985A priority patent/CA2609985A1/fr
Application filed by University of Chicago filed Critical University of Chicago
Publication of WO2007053194A2 publication Critical patent/WO2007053194A2/fr
Publication of WO2007053194A3 publication Critical patent/WO2007053194A3/fr
Anticipated expiration legal-status Critical
Priority to US13/483,932 priority patent/US20120316190A1/en
Priority to US14/061,331 priority patent/US20140142133A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés prophylactiques et thérapeutiques d'administration d'un antagoniste des récepteurs des µ-opioïdes pour traiter les maladies et les affections de la barrière cellulaire, par exemple les maladies et les affections de la barrière des cellules endothéliales et des cellules épithéliales. Les maladies ou affections concernés par les procédés sont l'inflammation, par exemple les lésions aiguës des poumons, l'athérosclérose, la septicémie d'origine viscérale, les lésions par brûlure, l'entérocolite nécrotique néonatale, la neutropénie grave, la colite toxique, les maladies inflammatoires des viscères, l'entéropathie, le rejet des transplants, la pouchite, l'entérite nécrotique, les infections ophtalmiques médiées par Pseudomonas, les infections otologiques médiées par Pseudomonas et les infections cutanées médiées par Pseudomonas. De manière plus générale, les procédés prophylactiques et thérapeutiques concernés peuvent être envisagés pour traiter les affections de la barrière des cellules épithéliales. Les maladies et les affections peuvent être induits par des pathogènes microbiens, notamment des pathogènes bactériens tels que Pseudomonas aeruginosa. L'invention concerne en outre des procédés prophylactiques et thérapeutiques qui inhibent l'expression de la lectine/adhésine PA-I bactérienne et d'inhibition des niveaux d'activité des MvfR bactériens. L'invention concerne également un procédé utilisant un antagoniste des récepteurs des µ-opioïdes pour la fabrication d'un médicament destiné à être utilisé dans les procédés qu'elle décrit.
PCT/US2006/021604 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire Ceased WO2007053194A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/914,984 US20080194611A1 (en) 2005-06-03 2006-05-06 Modulation of Cell Barrier Dysfunction
AU2006309292A AU2006309292A1 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction
EP06844131A EP1901742A2 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire
JP2008514938A JP2008542395A (ja) 2005-06-03 2006-06-05 細胞バリア機能障害の調整
CA002609985A CA2609985A1 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire
US13/483,932 US20120316190A1 (en) 2005-06-03 2012-05-30 Modulation of Cell Barrier Dysfunction
US14/061,331 US20140142133A1 (en) 2005-06-03 2013-10-23 Modulation of cell barrier dysfunction

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US68756805P 2005-06-03 2005-06-03
US60/687,568 2005-06-03
US73100905P 2005-10-28 2005-10-28
US60/731,009 2005-10-28
US76085106P 2006-01-20 2006-01-20
US60/760,851 2006-01-20
USPCT/US2006/07892 2006-03-07
PCT/US2006/007892 WO2006096626A2 (fr) 2005-03-07 2006-03-07 Utilisation d'antagonistes opioides pour l'attenuation de la proliferation et de la migration des cellules endotheliales

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007892 Continuation-In-Part WO2006096626A2 (fr) 2005-03-07 2006-03-07 Utilisation d'antagonistes opioides pour l'attenuation de la proliferation et de la migration des cellules endotheliales

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/914,984 A-371-Of-International US20080194611A1 (en) 2005-06-03 2006-05-06 Modulation of Cell Barrier Dysfunction
US13/483,932 Continuation US20120316190A1 (en) 2005-06-03 2012-05-30 Modulation of Cell Barrier Dysfunction

Publications (2)

Publication Number Publication Date
WO2007053194A2 WO2007053194A2 (fr) 2007-05-10
WO2007053194A3 true WO2007053194A3 (fr) 2007-08-09

Family

ID=38006351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021604 Ceased WO2007053194A2 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire

Country Status (3)

Country Link
EP (1) EP1901742A2 (fr)
CA (1) CA2609985A1 (fr)
WO (1) WO2007053194A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314442B2 (en) 2014-03-25 2016-04-19 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615646B2 (fr) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Formulations pharmaceutiques contenant de la methylnaltrexone
JP5241484B2 (ja) 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US7879870B2 (en) * 2006-04-19 2011-02-01 Smith Jill P Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP5461386B2 (ja) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
SI2139890T1 (sl) 2007-03-29 2014-12-31 Wyeth Llc Antagonisti perifernih opioidnih receptorjev in njih uporaba
MX351611B (es) 2007-03-29 2017-10-20 Wyeth Llc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
KR101173509B1 (ko) * 2007-10-05 2012-08-14 도레이 카부시키가이샤 모르피난 유도체 또는 그 약리학적으로 허용되는 산부가염을 유효 성분으로 하는 피부 성상 개선 치료약
JP5358587B2 (ja) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途
EP2306829B1 (fr) 2008-07-01 2017-01-04 University of Chicago Particules contenant un antagoniste périphérique de récepteur d'opioïde
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
CN117940554A (zh) * 2022-06-30 2024-04-26 上海羽冠生物技术有限公司 假单胞菌属的活细菌菌株
CN119613494B (zh) * 2025-02-12 2025-05-27 吉林农业大学 一种来源于鸡油菌子实体的抗氧化肽、抗氧化肽检测试剂及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20020173466A1 (en) * 1999-03-03 2002-11-21 Crain Stanley M. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
WO2006132963A2 (fr) * 2005-06-03 2006-12-14 The University Of Chicago Modulation d'interaction de pathogenes microbiens-cellules hotes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20020173466A1 (en) * 1999-03-03 2002-11-21 Crain Stanley M. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
WO2006132963A2 (fr) * 2005-06-03 2006-12-14 The University Of Chicago Modulation d'interaction de pathogenes microbiens-cellules hotes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZAGON I S ET AL: "OPIOID ANTAGONISTS INHIBIT THE GROWTH OF METASTATIC MURINE NEURO BLASTOMA", CANCER LETTERS, vol. 21, no. 1, 1983, pages 89 - 94, XP009083862, ISSN: 0304-3835 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US10137100B2 (en) 2010-09-23 2018-11-27 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US10772861B2 (en) 2010-09-23 2020-09-15 Leading Biosciences, LLC Administration of serine protease inhibitors to the stomach
US11439611B2 (en) 2010-09-23 2022-09-13 Leading BioSciences, Inc. Administration of serine protease inhibitors to the stomach
US9314442B2 (en) 2014-03-25 2016-04-19 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US9775821B2 (en) 2014-03-25 2017-10-03 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US11123317B2 (en) 2014-03-25 2021-09-21 Leading BioSciences, Inc. Compositions for the treatment of autodigestion

Also Published As

Publication number Publication date
CA2609985A1 (fr) 2007-05-10
WO2007053194A2 (fr) 2007-05-10
EP1901742A2 (fr) 2008-03-26

Similar Documents

Publication Publication Date Title
WO2007053194A3 (fr) Modulation des dysfonctionnements de la barriere cellulaire
MY161095A (en) Indole compound and pharmaceutical use thereof
WO2012149549A3 (fr) Bactéries bacillus à utiliser dans traitement et prévention d'infection chez des animaux aquatiques
WO2006132963A3 (fr) Modulation d'interaction de pathogenes microbiens-cellules hotes
EA201291441A1 (ru) Пробиотические штаммы для применения при улучшении состояния кишечной нервной системы
WO2009143150A3 (fr) Modulateurs de la phosphatase alcaline intestinale et leurs utilisations
WO2009041663A1 (fr) Agent destiné à la prévention et/ou au traitement de maladies cutanées
WO2009109654A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1
EA201171270A1 (ru) ПРИМЕНЕНИЕ НИФУРАТЕЛА В ЛЕЧЕНИИ ИНФЕКЦИЙ, ВЫЗВАННЫХ ВИДОМ Atopobium
WO2008036761A8 (fr) Peptides antimicrobiens apparentés aux défensines et leurs procédés d'utilisation
WO2008071961A8 (fr) Dérivés de 2-quinolinone et de 2-quinoxalinone et leur utilisation en tant qu'agents antibactériens
WO2007101264A3 (fr) Procédé servant à traiter des troubles des cellules endothéliales et épithéliales en administrant des composés de type peg de poids moléculaire élevé
WO2010125196A3 (fr) Bactériophages spécifiques aux souches pak et cha de pseudomonas aeruginosa et leurs applications
PH12013500401A1 (en) Quinoxaline compound
WO2009114878A3 (fr) Procédés et compositions pour une maladie génétique et rétinienne
WO2011091154A3 (fr) Utilisation d'érythrocytes humains dans la prévention et le traitement de la dissémination et de la croissance du cancer
WO2009068682A3 (fr) Dérivés phényle-oxétanyle
WO2007108004A3 (fr) Derives du s-alkylisothiouronium pour le traitement de maladies inflammatoires
IL218467A0 (en) Picrorhiza kurroa extract for prevention elimination and treatment of infection diseases
WO2005118613A3 (fr) Macrocycles d'amide antibacteriens
WO2011061554A3 (fr) Composition pharmaceutique pour le traitement des troubles de la vessie
RU2011146815A (ru) Способ получения препарата для активизации неспецифической резистентности, профилактики и терапии болезней молодняка сельскохозяйственных животных
EP3520794A3 (fr) Rôle de l'acide sulfonique n-2-hydroxy-éthyl-pipérazine-n'-2-éthane (hepes) dans la maîtrise de la douleur et guérison d'une lésion de la démyélinisation
Atif et al. Comparative analysis of the antibacterial, antifungal, antiproliferative and cyclic response element (CRE) induced expression of downstream luc gene activities of Monopterus albus and Channa straitus extracts
CN102552885A (zh) 海洋生物痔疮及肛内上皮和直肠粘膜上皮细胞消炎修护液

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006309292

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2609985

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008514938

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006844131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11914984

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06844131

Country of ref document: EP

Kind code of ref document: A2